Medical Professionals / Our Medicines & Products

Medicines and Products

Prescribing Information

Medication Guide

Healthcare Provider Letter

Safety Data Sheets

Alecensa® (alectinib)

Healthcare Provider Letters:

Important Drug Warning - December 2021

Safety Data Sheets:

ALECENSA(R) Capsules 150 mg

Avastin® (bevacizumab)

Healthcare Provider Letters:

Important Drug Warning - August 2024 Important Drug Warning: Necrotizing Fasciitis - Apr 2013 Warning for Counterfeit Product Labeled as Avastin in the United States Feb 2012 Important Change to Avastin® label for treatment of metastatic breast cancer - Nov 2011 Important New Safety Information in Women Receiving AVASTIN - Oct 2011 Intraocular Inflammatory Reactions - Dec 2008 Microangiopathic Hemolytic Anemia (MAHA) - July 2008 Tracheoesophageal (TE) Fistula - April 2007 Cases of RPLS in Patients Receiving AVASTIN - Sept 2006 VEGF antibodies for the treatment of retinopathy of prematurity - Aug 2006

Safety Data Sheets:

AVASTIN(R) Vials (100 mg) AVASTIN(R) Vials (400 mg)

Columvi™ (glofitamab-gxbm)

Safety Data Sheets:

COLUMVI(TM) 2.5 mg/2.5 ml COLUMVI(TM) 10 mg/10 ml

Cotellic® (cobimetinib)

Safety Data Sheets:

COTELLIC Tablets (20 mg)

Erivedge® (vismodegib)

Healthcare Provider Letters:

Important Drug Warning - November 2016 Serious Risk with Use of Erivedge (vismodegib) Capsules: Premature Epiphyseal Fusion - June 2016 Extension of Pregnancy Prevention Duration for Women of Childbearing Potential and Waiting Periods for Blood Donations and Lactation in Patients taking ERIVEDGE (vismodegib) capsule - February 2016

Safety Data Sheets:

ERIVEDGE(R) Capsules 150 mg

Gazyva® (obinutuzumab)

Healthcare Provider Letters:

Gazyva TM (obinutuzumab) Important Drug Warning: Thrombocytopenia - Feb 2014

Safety Data Sheets:

GAZYVA(R) Vials (1,000 mg/40 ml)

Herceptin® (trastuzumab)

Healthcare Provider Letters:

440mg Vials and Herceptin BWFI Diluent - June 2008 Updated Cardiotoxicity Information - Aug 2005 Fatal Embryo-Fetal Toxicity due to Herceptin Exposure During Pregnancy

Safety Data Sheets:

HERCEPTIN® Vials (150 mg)

Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)

Safety Data Sheets:

HERCEPTIN HYLECTA Vials (600 mg/5 ml)

Kadcyla® (ado-trastuzumab emtansine)

Healthcare Provider Letters:

Kadcyla Important Safety Warning: Hemorrhage, Nov 2013 KADCYLA (ado-trastuzumab emtansine) error on the carton - May 2013

Safety Data Sheets:

KADCYLA(R) Lyophilized Powder in Vials (100 mg) KADCYLA(R) Lyophilized Powder in Vials (160 mg) KADCYLA(R) Solution

Lunsumio™ (mosunetuzumab-axgb)

Healthcare Provider Letters:

Important Drug Warning - August 2024

Safety Data Sheets:

LUNSUMIO(TM) Vials (30 mg/30 ml) LUNSUMIO(TM) Vials (1 mg/ml)

Perjeta® (pertuzumab)

Safety Data Sheets:

PERJETA(R) (420 mg)

Phesgo® (pertuzumab, trastuzumab, and hyaluronidase-zzxf)

Safety Data Sheets:

PHESGO™ (pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (60 mg/ml, 60 mg/ml) PHESGO™ (pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80 mg/ml, 40 mg/ml)

Polivy® (polatuzumab vedotin-piiq)

Safety Data Sheets:

POLIVY(R) Vials (30 mg & 140 mg)

Rituxan® (rituximab [Oncology])

Healthcare Provider Letters:

Rituxan® (rituximab) Label: Hepatitis B Reactivation, October 2013 Important Drug Warning: Updated Safety Information - Dec 2006 Important Drug Warning: New Safety Information - Sept 2008 Important Drug Warning: Updated Safety Information - Oct 2009

Safety Data Sheets:

RITUXAN(R) Vials (100 mg/10 ml) RITUXAN(R) Vials (500 mg/50 ml)

Rituxan Hycela® (rituximab and hyaluronidase human)

Safety Data Sheets:

Rituxan Hycela (TM) Vials (1600 mg) Rituxan Hycela (TM) Vials (1400 mg)

Rozlytrek® (entrectinib)

Safety Data Sheets:

ROZLYTREK(R) Oral Pellets (50 mg) ROZLYTREK(TM) Capsules (100 mg) ROZLYTREK(TM) Capsules (200 mg)

Tarceva® (erlotinib)

Healthcare Provider Letters:

Important Prescribing Information - October 2016 Important Correction of Drug Information - June 2016

Safety Data Sheets:

TARCEVA(R) Tablets (25 mg) TARCEVA(R) Tablets (100 mg) TARCEVA(R) Tablets (150 mg)

Tecentriq® (atezolizumab)

Healthcare Provider Letters:

Important Drug Warning - August 2024 Important Prescribing Information - November 2022 Important Prescribing Information - August 2021 Important Prescribing Information - May 2021 Important Prescribing Information - March 2021 Follow Up Important Prescribing Information - March 2021 Important Drug Warning - August 2018 Important Prescribing Information - June 2018 Important Drug Warning - July 2017

Safety Data Sheets:

TECENTRIQ® Vials (840 mg/14 ml) TECENTRIQ® Vials (1,200 mg/20 ml)

Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs)

Safety Data Sheets:

TECENTRIQ Hybreza™ Vials 1,875 mg/15 ml

Venclexta® (venetoclax)

Safety Data Sheets:

VENCLEXTA(R) Tablets (10, 50 and 100 mg)

Xeloda® (capecitabine)

Safety Data Sheets:

XELODA(R) Tablets (150 mg) XELODA(R) Tablets (500 mg)

Zelboraf® (vemurafenib)

Healthcare Provider Letters:

Important Drug Warning - June 2017 Important Drug Warning - March 2014 Important Drug Warning - August 2013

Safety Data Sheets:

ZELBORAF(R) F.C. Tablets (240 mg)

Actemra® (tocilizumab)

Healthcare Provider Letters:

Important Prescribing Information - Temporary Supply Shortage Actemra 20 mg/mL Concentrate for Solution for Infusion (IV) September 2021 Apr 2020 - Shipping short-dated Actemra (tocilizumab) 400 mg/20 mL vial for IV with dark blue cap Important Drug Warning - 2019 IMPORTANT SAFETY INFORMATION Regarding ACTEMRA® (tocilizumab) REMS, October 2013 Actemra for RA and SJIA - June 2011 Actemra for RA and SJIA - Oct 2012

Safety Data Sheets:

ACTEMRA(R) SC Autoinjector (162 mg/0.9 ml) ACTEMRA(R) Sterile Concentrate for Injection (80 mg) ACTEMRA(R) SC Prefilled Syringes (162 mg/0.9 ml) ACTEMRA(R) Sterile Concentrate for Injection (200 mg) ACTEMRA(R) Sterile Concentrate for Injection (400 mg)

Esbriet® (pirfenidone)

Healthcare Provider Letters:

Important Drug Warning - August 2019

Safety Data Sheets:

Esbriet ® F.C. Tablets (267 mg) Esbriet ® F.C. Tablets (801 mg) Esbriet ® Capsules (267 mg)

Lucentis® (ranibizumab injection)

Healthcare Provider Letters:

New Warnings and Precautions: Retinal Vasculitis with or without Occlusion – March 2024 Counterfeit Product - November 2018 Important Drug Notification: Intraocular Inﬂammatory Reactions After Intravitreal Injection - Dec 2008 SAILOR with AMD - Jan 2007 Safety Risk with Intravitreal Use of VEGF - Aug 2006

Safety Data Sheets:

LUCENTIS(R) Prefilled Syringe (0.5 mg/0.05 ml) LUCENTIS(R) Prefilled Syringe (0.3 mg/0.05 ml)

Rituxan® (rituximab [Immunology])

Healthcare Provider Letters:

Rituxan® (rituximab) Label: Hepatitis B Reactivation, October 2013 Rituxan and PML - Oct 2009 Rituxan and RA - Sept 2008 Rituxan and the treatment of SLE - Dec 2006

Safety Data Sheets:

RITUXAN(R) Vials (100 mg/10 ml) RITUXAN(R) Vials (500 mg/50 ml)

Susvimo™ (ranibizumab injection)

Healthcare Provider Letters:

Important Prescribing Information - October 2022

Safety Data Sheets:

SUSVIMO 10MG/0.1ML VIAL

Vabysmo® (faricimab-svoa)

Healthcare Provider Letters:

Important Drug Warning – November 2023

Safety Data Sheets:

VABYSMO 12% aqueous solution

Xolair® (omalizumab)

Healthcare Provider Letters:

June 2021 - Important Prescribing Information April 2020 - Important Prescribing Information: Self-administration during the COVID-19 pandemic

Safety Data Sheets:

XOLAIR(R) PFS (300mg/2ml) XOLAIR(R) PFS (150 mg) XOLAIR(R) PFS (75 mg) XOLAIR(R) Vials (150 mg)

Nutropin AQ® ((somatropin) injection for subcutaneous use)

Safety Data Sheets:

NUTROPINAQ(R) NuSpin (5 mg/2 ml) NUTROPINAQ(R) Pen Cartridge and NuSpin (10 mg/2 ml) NUTROPINAQ(R) Pen Cartridge and NuSpin (20 mg/2 ml)

Activase® (alteplase)

Healthcare Provider Letters:

Stopper Dislodgement - How to reduce the risk of stopper dislodgement and leakage when using 100-mg vials

Safety Data Sheets:

ACTIVASE(R) Vials (50 mg) ACTIVASE(R) Vials (100 mg)

Enspryng® (satralizumab-mwge)

Safety Data Sheets:

ENSPRYNG™ SC (120 mg/ml)

Evrysdi® (risdiplam)

Healthcare Provider Letters:

Information Regarding Potential Leakage of Evrysdi (risdiplam) 0.75 mg/mL NDC 50242-175-07 Solution from Bottles Delivered to Patients

Safety Data Sheets:

EVRYSDI® (Risdiplam) 0.75 mg/ml EVRYSDI® Powder for Oral Solution (60 mg)

Ocrevus® (ocrelizumab)

Safety Data Sheets:

OCREVUS® Vials (300 mg/10 ml)

Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq)

Safety Data Sheets:

OCREVUS ZUNOVO™ Vials 920 mg/23ml

CellCept® (mycophenolate mofetil)

Healthcare Provider Letters:

Correction of labeling provided with CellCept® Intravenous and CellCept® Oral Suspension - May 2015 Important Changes in the CellCept® Prescribing Information - June 2008 Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) - 2012 Reports of Pure Red Cell Aplasia - Aug 2009 Pregnancy Notice - 2010 Pharmacists: Important New Dispensing Information - Jan 2009 Introduction of a CellCept Medication Guide - Jan 2009 Important Changes in the CellCept® Prescribing Information - Oct 2007

Safety Data Sheets:

CELLCEPT(R) Capsules (250 mg) CELLCEPT(R) Film Coated Tablets (500 mg) CELLCEPT(R) Oral Suspension CELLCEPT(R) Lyophilized Vials (500 mg) CELLCEPT(R) Powder for Oral Suspension

Pegasys® (peginterferon alfa-2a)

Safety Data Sheets:

PEGASYS(R) Vials (180 mcg/ml) PEGASYS(R) Prefilled Syringe (180 mcg/0.5 ml) PEGASYS ProClick(TM) Autoinjector (180 mcg/0.5 ml)

Pulmozyme® (dornase alfa)

Safety Data Sheets:

Pulmozyme(R) Inhalation Solution (2.5 mg)

Tamiflu® (oseltamivir phosphate)

Healthcare Provider Letters:

Tamiflu Dear Pharmacist Letter Removal of Dosing Dispenser-Aug 2013 Important Prescribing Information for Patients Under 1 - Jan 2013

Safety Data Sheets:

TAMIFLU(R) Capsules (30 mg) TAMIFLU(R) Capsules (45 mg) TAMIFLU(R) Capsules (75 mg) TAMIFLU(R) Suspension (6 mg/ml) TAMIFLU(R) Powder for Oral Suspension (30 mg/5ml)

Valcyte® (valganciclovir hydrochloride)

Healthcare Provider Letters:

Important Prescribing Information - July 2021

Safety Data Sheets:

VALCYTE(R) Powder for Oral Solution (50 mg/ml) VALCYTE(R) F.C. Tablets (450 mg)

Xofluza® (baloxavir marboxil)

Healthcare Provider Letters:

Important Prescribing Information - October 2019

Safety Data Sheets:

XOFLUZA(TM) Granules for Oral Suspension XOFLUZA(TM) Reconstituted Oral Suspension (2 mg/ml) XOFLUZA(TM) Tablets (40 mg)

Actemra® (TOCILIZUMAB [authorized for Emergency Use])

Cathflo Activase® (alteplase)

Healthcare Provider Letters:

Important Drug Warning - May 2024 Important Drug Information: New rubber stoppers now available - Dec 2014 Important Drug Information: Filtering Instructions for Pharmacists - Mar 2013

Safety Data Sheets:

CATHFLO ACTIVASE(R) Vials (2 mg)

Floodlight™ (MS)

Fuzeon® (enfuvirtide)

Safety Data Sheets:

FUZEON(R) Lyophilized Vials (90 mg)

Hemlibra® (emicizumab-kxwh)

Safety Data Sheets:

HEMLIBRA™ (30 mg/1.0 ml) HEMLIBRA™ (60 mg/0.4 ml) HEMLIBRA™ (105 mg/0.7 ml) HEMLIBRA™ (150 mg/1.0 ml) HEMLIBRA™ (12 mg/0.4 ml) HEMLIBRA™ (300 mg/2.0 ml)

PiaSky® (crovalimab-akkz)

Safety Data Sheets:

PIASKY® (340 mg/2 ml)

TNKase® (tenecteplase)

Healthcare Provider Letters:

Recall of Triad Group Alcohol Prep Products Due to Potential Microbial Contamination - Jan 2011

Safety Data Sheets:

TNKase(R) Lyophilized Powder (50 mg)

Valium® (diazepam)

Healthcare Provider Letters:

Serious risks with use of KLONOPIN® and/or VALIUM® - Feb 2021 Important Drug Warning - January 2017

Safety Data Sheets:

VALIUM(R) Tablets (2 mg) VALIUM(R) Tablets (5 mg) VALIUM(R) Tablets (10 mg)

Access to Investigational Medicines
We're committed to a fair and impartial evaluation of each request for access to our investigational medicines.
Genentech iMedConnect
Scientific and clinical information for U.S. Healthcare Providers.
Find Open Clinical Trials
Search clinicaltrials.gov to find out if a trial exists for a specific medicine for a particular disease.

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Medicines and Products

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

Healthcare Provider Letters:

Safety Data Sheets:

You Might Also Be Interested In